Leap Therapeutics

$1.96
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.12 (-5.77%) As of 11:00 AM EDT today

Why Robinhood?

You can buy or sell LPTX and other stocks, options, and ETFs commission-free!

About LPTX

Leap Therapeutics, Inc. Common Stock, also called Leap Therapeutics, is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. Read More Its clinical stage programs are DKN-01, which is a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1 and TRX518, which is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor, or GITR. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA. The listed name for LPTX is Leap Therapeutics, Inc. Common Stock.

Employees
26
Headquarters
Cambridge, Massachusetts
Founded
2011
Market Cap
115.55M
Price-Earnings Ratio
Dividend Yield
Average Volume
566.26K
High Today
$2.04
Low Today
$1.93
Open Price
$2.02
Volume
177.50K
52 Week High
$3.18
52 Week Low
$0.5728

Collections

LPTX Earnings

-$0.55
-$0.37
-$0.18
$0.00
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Q3 2020
Estimated
per share
Actual
Expected Nov 12, Pre-Market

You May Also Like